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Background. Spasticity is prevalent and disabling in persons with multiple sclerosis (MS), and the development of the Multiple
Sclerosis Spasticity Scale-88 (MSSS-88) provides an opportunity for examining the perceived impact of spasticity and its
association with gait in this population. Purpose. This study examined the association between the perceived impact of spasticity
and spatio-temporal parameters of gait in persons with MS. Methods. The sample included 44 adults with MS who completed the
MSSS-88 and 4 walking trials on a 26-foot GAITRiteTM electronic walkway for measurement of spatio-temporal components of
gait including velocity, cadence, base of support, step time, single support, double support, and swing phase. Results. The overall
MSSS-88 score was signiﬁcantly associated with velocity (r =− 0.371), cadence (r =− 0.306), base of support (r = 0.357), step
time (r = 0.305), single leg support (r =− 0.388), double leg support (r = 0.379), and swing phase (r =− 0.386). Conclusions.
The perceived impact of spasticity coincides with alterations of the spatio-temporal parameters of gait in MS. This indicates that
subsequent interventions might target a decrease in spasticity or its perceived impact as an approach for improving mobility in
MS.
1.Introduction
Multiple sclerosis (MS) is an inﬂammatory, neurodegenera-
tive disease of the central nervous system (CNS). The disease
process itself results in the demyelination and transection
of axons in the brain, spinal cord, and optic nerves [1].
This axonal damage delays or blocks the propagation of
electrical potentials along neuronal pathways in the CNS
[2] and the extent and location of damage manifests in the
heterogeneous expression of symptoms [3].
Spasticity deﬁned as the velocity-dependent increase in
the muscle stretch reﬂex, and exaggerated tendon jerks re-
sulting from hyperactivity of motor components to sensory
input [4] is a common, disabling, and potentially self-lim
iting symptom of MS that requires a patient-focused, multi-
disciplinary approach for management [5]. Spasticity itself
aﬀe c t su p w a r d so f9 0 %o fp e r s o n sw i t hM S[ 6, 7], typically
presents in the lower legs (i.e., calf muscles), and has been
associatedwithworsemobilitydisability[7–9].Todate,there
is limited information on the patient’s perceived impact of
spasticity and its association with temporal and spatial para-
meters of gait that are targets of gait rehabilitation in MS.
This is important as perceptions of the impact of spasticity
might represent a target of therapeutic interventions for gait
rehabilitation.
Recognizing the importance of capturing the perceived
impact of spasticity for its eventual management, researchers
undertook a systematic development and comprehensive
psychometric evaluation of the Multiple Sclerosis Spasticity
Scale-88 (MSSS-88) [10]. The MSSS-88 emerged as a reliable
and valid patient-reported outcome of the perceived burden
of spasticity for impacting a patient’s life. This scale has the
potential for advancing our understanding of the perceived
impact of spasticity in clinical trials and practice involving
persons with MS. Such an opportunity is important as spas-
ticity management should be patient-focused and account
for the impact of a patient’s experiences and perceptions of
spasticity in impacting everyday life activity such as walking
mobility. To that end, one ﬁrst step for actualizing this2 ISRN Neurology
potential involves examining the association between MSSS-
88 scores and temporal and spatial parameters of gait.
This laboratory-based study examined the association
between the patient’s perceived impact of spasticity and
temporal and spatial markers of gait using MSSS-88 scores
and the GAITRiteTM electronic walkway, respectively. The
GAITRiteTM electronic walkway provides a rapid, clinically
relevant measurement of spatio-temporal gait components
including velocity, cadence, base of support, step time,
single and double support, and swing phase and has been
validated in MS [11, 12]. The present examination is
important for identifying the possible association between
the patient’s perception of spasticity and gait itself—an
important component of everyday life function. We further
note that this examination was motivated by the possibility
that patient-focused, clinical trials and practice might target
the perception of spasticity and its impact as a means of
improving mobility in MS. We expected that the perception
of spasticity would be associated with worse spatial and
temporal characteristics of gait in persons with MS such that
MSSS-88 scores would be positively correlated with base of
support, step time, and double leg support and negatively
correlated with cadence, velocity, single leg support, and
swing phase.
2. Methods
2.1. Participants and Procedures
The procedure was approved by an Institutional Review
Board, and participants provided appropriately obtained
written informed consent. We recruited a sample of persons
with MS through direct contact with support groups of a
Midwestern chapter of the National Multiple Sclerosis Soci-
ety that were located within an approximately 90-minute
drive from our campus. The inclusion criteria involved a
clinically deﬁnitive diagnosis of MS, relapse-free during
the past 30 days, ambulatory, 18–64 years of age, and
having the visual ability necessary to read 14-point font.
W es c r e e n e d6 9p e r s o n sw i t hM Sa n d4 4w e r ee n r o l l e d
in the study. On a single testing session, the participants
provided demographic and clinical information, completed
the MSSS-88, and performed 4 trials of walking on the
GAITRiteTM electronic walkway for measuring spatial and
temporal parameters of gait.
2.2. Primary Measures
2.2.1. MSSS-88. The MSSS-88 is a self-reported measure
of the burden of spasticity in persons with MS [10]. This
scale has 88 items that are rated on a 4-point scale of 1
(Not at all bothered) through 4 (Extremely bothered). The
items correspond with 8 subscales of Muscle Stiﬀness, Pain
and Discomfort, Muscle Spasms, Activities of Daily Living,
Walking, Body Movements, Emotional Health, and Social
Functioning. The overall measure of spasticity burden was
computed by averaging the mean scores for the 8 subscales
on the MSSS-88 [13].
Table 1: Mean, standard deviation and range of subscales.
Mean ± SD Range
MSSS overall 1.4 ±0.4 1–2.6
MSSS muscle 1.5 ±0.5 1–2.9
MSSS pain 1.5 ±0.6 1–3.4
MSSS spasms 1.2 ±0.3 1–2.2
MSSS activity 1.2 ±0.4 1–3.0
MSSS walking 1.6 ±0.7 1–3.3
MSSS body 1.3 ±0.5 1–2.7
MSSS feeling 1.3 ±0.5 1–2.8
MSSS social 1.3 ±0.5 1–2.5
MSSS: Multiple Sclerosis Spasticity Scale.
2.2.2. GAITRite. Participants completed 4 trials of walking
on a 26-foot GAITRiteTM (CIR systems, Inc) electronic
walkway at a comfortable pace as done in previous research
involving persons with MS [11, 12]. The GAITRiteTM system
is a computerized instrument with sensors arranged in a
gridlike pattern for identifying footfall contacts. The system
provides cadence, stride length, step time, base of support,
and percentages of gait cycle spent in double support,
single support, and swing phase as spatial and temporal
measures of gait. We recorded the cadence (steps/min),
velocity (cm/sec), step time (sec), base of support (cm),
single leg support (%), double leg support (%), and swing
phase (%) for each of the 4 trials. The average of the 4
trials for each variable was used in the analysis for improved
reliability.
2.2.3. PDDS. The Patient Determined Disease Steps (PDDS)
is a self-report scale that measures walking mobility using an
ordinalscaleof0(Normal)through8(Bedridden).Thisscale
was developed as an inexpensive surrogate for the Expanded
Disability Status Scale (EDSS) and scores from the PDDS
are linearly and strongly related with physician-administered
EDSS scores (r = .93) [14].
2.3. Data Analysis. Descriptive and inferential data analyses
were conducted using SPSS version 18 (SPSS Inc, Chicago,
Illinois). We ﬁrst provided descriptive statistics including
mean, standard deviation (SD), and range of scores for the
MSSS-88 and spatial and temporal parameters from the
GAITRiteTM. We then provided inferential statistics for the
relationship between MSSS-88 scores and the spatial and
temporal parameters of gait based on bivariate correlation
analysis using Pearson product-moment correlation coeﬃ-
cients (r). The alpha-value for statistical signiﬁcance was
0.05.
3. Results
3.1. Sample Characteristics
The study participants were ambulatory women (n = 38)
and men (n = 6) with a deﬁnite diagnosis of MS. TheISRN Neurology 3
Table 2: Mean, standard deviation, and range of spatial and temporal parameters of gait.
Mean ± SD Range Mean (Previous study results)
Cadence (steps/min) 112 ±8 90–130 94.4
Velocity (cm/sec) 127.8 ± 20.9 81.4–183.5 85.5
Step time (sec) 0.5 ±0.04 0.5–0.7 0.67(R)
0.65(L)
Base of support (cm) 10.3 ±4 1.5–22.8 11.6(R)
11.6(L)
Single leg support (%) 36.3 ±2.1 30.3–40.2 37.3(R)
36.7(L)
Double leg support (%) 27.7 ±4.2 19.8–39.6 24.6(R)
24.9(L)
Swing phase (%) 36.3 ±2.1 30.3–40.3 39.1(R)
39.8(L)
Previous study results [11].
Table 3: Bivariate correlations among MSSS-88 components and gait parameters during walking on a GAIRiteTM system.
Cadence
(steps/min)
Velocity
(cm/sec)
Step time
(sec)
Base of
support (cm)
Single leg
support (%)
Double leg
support (%)
Swing phase
(%)
Overall MSSS-88 −0.31∗ −0.37∗ 0.31∗ 0.36∗ −0.39 0.38∗ −0.39
MSSS-Muscle −0.32∗ −0.35∗ 0.31∗ 0.35∗ −0.39 0.38∗ −0.39
MSSS- Pain −0.20 −0.32∗ 0.19 0.39 −0.32∗ 0.31∗ −0.32∗
MSSS-Spasm −0.23 −0.32∗ 0.23 0.40 −0.40 0.39 −0.40
MSSS-Activity −0.20 −0.32∗ 0.21 0.17 −0.36∗ 0.35∗ −0.36∗
MSSS-Walking −0.31∗ −0.35∗ 0.31∗ 0.39 −0.26 0.25 −0.26
MSSS- Body −0.30 −0.31∗ 0.29 0.39 −0.39 0.39 −0.39
MSSS-Feeling −0.20 −0.24 0.21 0.11 −0.24 0.22 −0.23
MSSS-Social −0.25 −0.25 0.26 0.11 −0.30∗ 0.29 −0.30
∗Correlation is signiﬁcant at the 0.05 level (2-tailed).
MSSS: Multiple Sclerosis Spasticity Scale.
mean ± SD age of the sample was 47 ± 9 years, and the
sample primarily had relapsing-remitting MS (n = 38; 86%)
with a mean ± SD disease duration of 11 ± 8y e a r sa n d
a median PDDS score of 1 (Interquartile Range (IQR) = 0
and 3).
3.2. Descriptive Statistics
3.2.1. Spasticity. MSSS-88 data from this study are reported
in Table 1. The mean MSSS-88 score in the present study
was lower than that reported in a previous study [13]o f
∼1.9. This is expected because that previous study recruited
participants with spasticity based on modiﬁed Ashworth
Scale (MAS) scores between 1 and 3.
3.2.2. Spatial and Temporal Parameters. Data for the spatial
and temporal parameters of gait are reported in Table 2.
The sample had a faster cadence, step time, and velocity
when compared with a previous study [11]. This diﬀerence
is expected and explained by the lower level of disability
in the present study compared with the previous study
[11].
3.3. Bivariate Correlation Analysis. The correlations between
overall MSSS-88 scores with spatial and temporal param-
eters of gait are provided in Table 3. Scatter plots of the
associations between MSSS-88 and cadence, velocity, step
t i m e ,b a s eo fs u p p o r t ,s i n g l el e gs u p p o r t ,d o u b l el e gs u p p o r t ,
and swing phase are provided in Figure 1. Collectively, the
overall MSSS-88 score was signiﬁcantly correlated with gait
components: velocity (r =− 0.371, P = 0.007), cadence
(r =− 0.306, P = 0.022), base of support (r = 0.357; P =
0.009), step time (r = 0.305; P = 0.022), single leg support
(r =− 0.388, P = 0.005), double leg support (r = 0.379,
P = 0.006), and swing phase (r =− 0.386, P = 0.005).
There further were signiﬁcant associations between
MSSS-88 subscales and spatial and temporal parameters
of gait as reported in Table 3. The strongest pattern of
correlations emerged for the perceived muscular burden of
spasticity, whereas the weakest pattern of correlation existed
for the feeling or emotional burden of spasticity.
4. Discussion
The novel ﬁnding of the present study was that the per-
ceived impact of spasticity was associated with spatial and4 ISRN Neurology
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Figure 1:Scatterplot,lineartrendline,and90%conﬁdenceintervalsfortheassociationbetweenMSSS-88andcadence(steps/min),velocity
(cm/sec), step time (sec), base of support (cm), single leg support (%), double support (%), and swing phase (%).
temporal parameters of gait. Those who reported a greater
overall burden of spasticity had worse spatial and temporal
parameters of gait, namely, reduced cadence, velocity, single
leg support, and swing phase as well as increased step time,
base of support, and double leg support. The subscales of
the MSSS-88 were further associated with the parameters of
gait. This extends previous research reporting that clinical
measuresofspasticity areassociatedwithworseperformance
onmobility outcomemeasuresinpersonswithMS[7,9,15].
Collectively, this body of research indicates that spasticity
and its perceived impact are associated with worse mobility,
andourdatafurtherindicatethattheperceptionofspasticity
and its burden might represent an important target of
gait rehabilitation as gait is the physical manifestation of
walking.
Our study is diﬀerent from previous study [9, 15] in that
we measured the patient’s perspective on spasticity and its
impactongaitkinematics,whereaspreviousstudiesincluded
clinical methods of measuring spasticity and its impact on
ambulatory performance. For example, one study of persons
with MS measured spasticity by the MAS and reported that
worse leg spasticity was associated with worse walking speed,
endurance, and balance indicated by worse performance
on T25FW, 6-Minute Walk Test (6MWT), and Berg Bal-
ance Scale, respectively [9]. An additional study measured
spasticity based on the amplitude of the soleus H-reﬂex
(electrophysiological marker of spasticity) and reported that
itwasassociatedwithposturalswaywhileonaforceplatform
[15]. By comparison, the present study primarily focused on
the perceived impact of spasticity and gait kinematics (i.e.,
the physical basis of walking) and reported that MSSS-88
scores were associated with spatial and temporal parameters
of gait. Collectively, this indicates that the manifestation and
perception of spasticity are associated with worse mobility,
including gait kinematics, in persons with MS.
One possible implication of our research is that the
perceived impact of spasticity represents an important target
of therapies for improving mobility and gait in MS. Whereas
many therapies have been developed for targeting spasticity
itself (e.g., pharmacotherapy, muscle stretching, whole-body
vibration), there is very limited information on approaches
for targeting the perceived impact of spasticity in MS.
Exercise training might represent a possible approach for
reducing the perceived impact of spasticity in MS. Indeed,
one study adopted a quasi-experimental design and reported
that a 4-week period of unloaded leg-cycling exercise was
eﬀective for reducing MSSS-88 scores compared with a
control condition, but the exercise training did not change
electrophysiological and clinical markers of spasticity in
p e r s o n sw i t hM S[ 13]. This is similar with other research
indicating that exercise training is eﬀective for reducing
the perceived impact of spasticity based on MSSS-88 scores
in persons with MS [16, 17]. Beyond exercise training,
self-management strategies might be an additional route
for reducing the perceived impact of spasticity in MS. Such
strategies include gaining knowledge about factors that
can trigger spasticity including postural change, diurnal
variations, incomplete emptying of bladder/bowel, pressure
sores, tight clothing, emotions, and stress [18]. There are
likely to be other strategies for reducing the perceived impact
of spasticity in MS, and a critical step in such eﬀorts will
involve examinations of the secondary eﬀects on walking
performance and gait kinematics, particularly as some
therapies that are eﬀective for reducing spasticity can have
negativeeﬀectslikemuscleweakness,fatigue,andparesthesia
[19].
Overall, this laboratory-based, cross-sectional study pro-
vides novel evidence that overall perceived impact of spas-
ticity coincides with alterations in spatial and temporal
parameters of gait in persons with MS. This highlights the6 ISRN Neurology
importanceofconsideringthepatient’sperspectiveregarding
the impact of spasticity as a target of an intervention for
improving mobility and gait kinematics in MS. Collectively,
additional research is required that identiﬁes methods and
approaches for managing the perceived impact of spasticity
as this holds promise to be a signiﬁcant component of
improving mobility and gait in persons with MS who have
spasticity.
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